Sanofi

Photo
20.02.2025 • News

Sanofi and CD&R Sign Share Purchase Agreement for Opella

Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).

Photo
21.10.2024 • News

Sanofi in Talks to Sell Stake in Opella to CD&R

Sanofi has entered into talks with Clayton Dubilier & Rice (CD&R), a US-based investment company, about the potential sale of a 50% controlling stake in the French drugmaker‘s consumer healthcare business, Opella.

Photo
14.05.2024 • News

Sartorius and Sanofi Collaborate to Boost Downstream Process Efficiency

Life science group Sartorius and biopharmaceutical firm Sanofi are partnering to create a platform for continuous downstream bioprocessing. Sartorius will use its engineering and manufacturing skills to commercialize integrated and continuous biomanufacturing (ICB) platforms, using Sanofi’s prototypes. In exchange, Sanofi will provide Sartorius with exclusive access to its ICB platform knowledge and patents.

Photo
20.03.2024 • NewsChemistry

The Future of mRNA Technology

mRNA-based vaccines against the coronavirus have become firmly established in medicine since the pandemic. Nevertheless, the technology is still at the beginning of its potential. Experts see a wide range of potential applications for this relatively new technology, particularly in infectious diseases and cancer.

Photo
11.03.2024 • News

SK Bioscience to Expand South-Korean Vaccine Production Capacity

South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion.

Photo
23.01.2024 • News

Sanofi to Acquire Inhibrx for $1.7 Billion

Sanofi agreed to acquire biopharmaceutical company Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx for approximately $1.7 billion and will also retain an 8% equity stake in New Inhibrx. Sanofi said that it expects to finance the transaction with available cash resources.

Photo
04.10.2023 • News

Sanofi Enters into Partnerships with Janssen and Teva

Sanofi has entered into an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, a potential first-in-class product currently in Phase 3.

Photo
17.05.2023 • NewsStrategy

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

Photo
21.03.2023 • News

Global Pharma Reduces Marketing Staff in India

As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.

Photo
20.03.2023 • News

Sanofi in Lockstep with US Insulin Price Cuts

The world's largest insulin producers, Eli Lilly, NovoNordisk and Sanofi are now marching (almost) in lockstep to reduce US market prices, but not without tossing sideward barbs at the system.

Photo
16.03.2023 • News

Novo Nordisk to Cut US Insulin prices from 2024

Danish drugmaker Novo Nordisk has added its name to the list of insulin producers cutting prices for US retail buyers, following up on Eli Lilly’s announcement of price cuts and in response to growing pressure from the White House.

Photo
15.03.2023 • News

Sanofi Buying Diabetes Specialist Provention Bio

Paris-based French drugmaker Sanofi has agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of about $2.9 billion. The publicly traded US biopharma focuses on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D).

Photo
14.03.2023 • News

Lilly Insulin Price Cut Revives US Discussion

As the discussion surrounding the high price of insulin in the US continues unabated, drugmaker Eli Lilly implemented price reductions of 70% for its most commonly prescribed insulin products at the beginning of March.

Photo
19.01.2023 • News

Sanofi Strengthens Venture Capital Budget

As well as serving as a financial partner to fledgling companies, the VC fund supports future efforts for business development and M&A opportunities within its own operations, Sanofi said. The fresh capital injection will also fuel the expansion and investment capacity of its own investment team on a global scale.

Photo
12.01.2023 • News

EuroAPI Invests €40 Million in French B12 Production

Leading active pharmaceutical ingredients manufacturer EuroAPI plans to invest €40 million at its site in Saint-Aubin-lès-Elbeuf, France, to launch a new production technology for vitamin B12. Full capacity is expected to be reached by 2027.

Photo
11.11.2022 • News

EU Approves Sanofi/GSK Covid Booster

After several delays and restarts and a lengthy review by the European Medicines Agency (EMA), the Covid-19 vaccine called VidPrevtyn Beta developed by the French-British partnership of Sanofi and GSK has been greenlighted by the European Commission.

Photo
08.11.2022 • News

Pharma CEOs Take Action on Climate Change

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.

Photo
14.10.2022 • News

CDMO Adragos to Buy Sanofi Site in Japan

Munich-based German CDMO Adragos Pharma said it has signed a definitive agreement with Sanofi’s Japanese subsidiary to acquire a pharmaceutical manufacturing site in Kawagoe, near Tokyo.

Photo
29.07.2022 • News

EuroAPI to Invest in Biomass Boiler in France

EuroAPI has announced it will spend €24 million to build a state-of-the-art biomass boiler at its Saint-Aubin-lès-Elbeuf (Seine-Maritime, France) site, planned to be installed by 2025.

Photo
05.07.2022 • News

Sanofi Joins Pfizer in nonprofit Drug Distribution

Two globally oriented drugmakers, Pfizer and Sanofi, are making moves that some may interpret as attempts to allay the pharma industry‘s reputation for being “only in it for the money” but could potentially benefit poorer countries if all goes to plan.

Photo
27.04.2022 • News

Sanofi Teams up with McLaren Racing

Sanofi has joined forces with McLaren Racing in a move it hopes will accelerate its manufacturing efficiency and performance drive. As the French drugmaker’s CEO Paul Hudson put it, “we want to run our lines with the speed, precision and efficiency of a Formula One racing team.”

Photo
04.04.2022 • News

EuroAPI’s Euronext Listing Set for May 6

Sanofi has announced it will list its Active Pharmaceutical ingredients company EuroAPI on the Euronext stock exchange in Paris on May 6. Each of the French drugmaker’s shareholders will receive one share in EuroAPI for 23 Sanofi shares in addition to a cash dividend of €3.33 per Sanofi share.

Photo
31.03.2022 • News

Sanofi in Billion-Dollar Collaboration With IGM

French drugmaker Sanofi has signed an exclusive worldwide collaboration agreement with IGM Biosciences, a clinical-stage biotechnology company. The deal focuses on creating and developing and commercializing engineered IgM antibody antagonists against three oncology targets, along with three immunology/inflammation targets.

Photo
16.03.2022 • News

Sanofi and Blackstone in €300 Million Collaboration

Sanofi has agreed a €300 million collaboration with private equity investor Blackstone Life Sciences (BXLS) to advance its innovative treatment for multiple myeloma (MM) Sarclisa (isatuximab). The French drugmaker said it will continue to fully manage the clinical program and retain full rights and control of the treatment.

Photo
16.12.2021 • News

Sanofi/GSK Covid Shot Shows Booster Promise

In the VAT 0002 extension trial investigating the safety and immunogenicity of the protein-based recombinant adjuvanted Covid-19 vaccine they are partly developing as a booster, Sanofi and GlaxoSmithKline said the shot delivered a “consistently strong immune response” and was well tolerated, regardless of the vaccine it followed.

408 more articles

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.